(CercleFinance.com) – Noxxon announced today that it will adapt its strategy in order to better focus on the treatment of brain cancer after obtaining encouraging clinical results in this particularly aggressive cancer.
The biotech explains that this decision follows the positive data obtained within the framework of the phase 1/2 study with NOX-A12, its main candidate, associated with radiotherapy.
Data presented today also show that the triple combination of NOX-A12 with radiation therapy and bevacizumab not only resulted in tumor shrinkage in 100% of patients, but also partial radiographic response in all patients with of glioblastoma.
Based on these findings, Noxxon says it plans to seek guidance from regulators on how to proceed for approval when tracking these patients is more advanced, likely in Q4 2022.
This means that the company will now focus its investments on NOX-A12 for the treatment of glioblastoma in order to maximize its chances of entering the market as quickly as possible.
This announcement was welcomed by investors since the Noxxon share price rose nearly 5% Thursday at midday on the Paris Stock Exchange after having jumped more than 12% during the morning.
It should also be noted that the shares resulting from the consolidation will be admitted to trading on the Euronext Growth Paris market from July 28, the first day of trading for the new shares.